ACRS - Spark Newswire

2 minute read

Earnings

Aclaris Therapeutics’s Return On Capital Employed Insights

June 8, 9:52 AM

According to data from Benzinga Pro, during Q1, Aclaris Therapeutics's (NASDAQ:ACRS) reported sales totaled $1.45 million. Despite a 17.61% increase in earnings, the company posted a loss of $18.79 million.

ACRS

3 minute read

Mid-Afternoon Market Update: Nasdaq Rises 50 Points; Jefferies Shares Drop

By Lisa Levin

January 12, 3:56 PM

Toward the end of trading Wednesday, the Dow traded up 0.05% to 36,269.24 while the NASDAQ rose 0.35% to 15,205.90. The S&P also rose, gaining, 0.26% to 4,725.52.

ACRS

2 minute read

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

January 12, 1:35 PM

ACRS

3 minute read

Mid-Day Market Update: Crude Oil Rises 2%; Philips Shares Plummet

By Lisa Levin

January 12, 1:32 PM

Midway through trading Wednesday, the Dow traded up 0.26% to 36,346.85 while the NASDAQ rose 0.77% to 15,270.07. The S&P also rose, gaining, 0.57% to 4,739.98.

ACRS

2 minute read

Aclaris Therapeutics Offers R&D Update

By Benzinga Newsdesk

January 11, 5:01 PM

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today provides an update on the status of certain of its

ACRS

2 minute read

Earnings

Looking Into Aclaris Therapeutics’s Return On Capital Employed

By Benzinga Insights

November 2, 11:51 AM

Benzinga Pro data, Aclaris Therapeutics (NASDAQ:ACRS) reported Q3 sales of $1.66 million. Earnings fell to a loss of $20.30 million, resulting in a 12.71% decrease from last quarter.

ACRS

1 minute read

Aclaris Therapeutics Q3 EPS $(0.35) Down From $(0.25) YoY, Sales $1.66M Up From $1.45M YoY

By Benzinga Newsdesk

November 2, 7:24 AM

Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.35) per share. This is a 40 percent decrease over losses of $(0.25) per share from the same period last year. The company reported $1.66 million in

ACRS

1 minute read

12 Health Care Stocks Moving In Thursday’s Pre-Market Session

By Benzinga Insights

September 16, 8:15 AM

ACER

3 minute read

The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself

By Shanthi Rexaline

September 3, 7:31 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2)

ABT

1 minute read

Earnings

Looking into Aclaris Therapeutics’s Return on Capital Employed

By Benzinga Insights

August 27, 5:13 PM

After pulling data from Benzinga Pro it seems like during Q2, Aclaris Therapeutics's (NASDAQ:ACRS) reported sales totaled $1.82 million. Despite a 36.89% in earnings, the company posted a loss of $18.01 million.

ACRS

Feed Symbols: ACRS